Global Information
회사소개 | 문의 | 비교리스트

세계의 의약품 수탁개발제조 시장 예측(-2029년) : 서비스별, 최종사용자별

Pharmaceutical Contract Development & Manufacturing Market by Service, End User [Large Pharma, Generic] - Global Forecast to 2029

리서치사 Meticulous Market Research Pvt. Ltd.
발행일 2022년 06월 상품코드 1087858
페이지 정보 영문 216 Pages 배송안내
가격
US $ 4,175 ₩ 5,484,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄는 1회에 한해 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,875 ₩ 7,717,000 PDF (Multi User License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄는 5회에 한해 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,875 ₩ 10,344,000 PDF (Global Site License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 의약품 수탁개발제조 시장 예측(-2029년) : 서비스별, 최종사용자별 Pharmaceutical Contract Development & Manufacturing Market by Service, End User [Large Pharma, Generic] - Global Forecast to 2029
발행일 : 2022년 06월 페이지 정보 : 영문 216 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 의약품 수탁개발제조 시장 규모는 2029년까지 2,263억 5,000만 달러에 달하고, 2022-2029년에 CAGR로 7.5%의 성장이 예측됩니다. 시장 성장은 주로 복잡한 제조 요건, 특허 만료, 의약품 연구개발에 대한 투자 증가, 의약품 업계의 최첨단 기술로의 지향, 코로나바이러스 유행 등에 기인하고 있습니다.

세계의 의약품 수탁개발제조(Pharmaceutical Contract Development & Manufacturing) 시장에 대해 조사 분석했으며, 시장 인사이트, 서비스·최종사용자별 분석, 경쟁 상황 등을 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

  • 서론
  • 성장 촉진요인
  • 과제
  • 시장 기회
  • 업계 동향

제5장 의약품 수탁개발제조 시장 : 서비스별

  • 서론
  • 의약품 제조 서비스
    • 원료의약품(API) 제조 서비스
    • 최종 제제(FDF) 제조 서비스
  • 의약품 개발 서비스
  • 생물제제 제조 서비스
    • 원료의약품(API) 제조 서비스
    • 최종 제제(FDF) 제조 서비스

제6장 의약품 수탁개발제조 시장 : 최종사용자별

  • 서론
  • 대형 제약 기업
  • 중소 제약 기업
  • 제네릭 제약 기업

제7장 의약품 수탁개발제조 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카

제8장 경쟁 상황

  • 서론
  • 주요 성장 전략
  • 경쟁 벤치마킹
  • 시장 점유율 분석(2021년) - 상위 19개사
    • Lonza Group Ltd.(스위스)
    • Catalent INC.(미국)
    • Thermo Fisher Scientific INC.(미국)
    • Samsung Biologics Co., Ltd.(한국)
    • Recipharm AB(스웨덴)

제9장 기업 개요(사업 개요, CDMO 시설, 재무 개요, 서비스 포트폴리오, 전략적 개발)

  • Cambrex Corporation
  • Samsung Biologics Co., Ltd.
  • Siegfried Holdings AG
  • FUJIFILM Diosynth Biotechnologies
  • Aenova Group
  • Wuxi Biologics, Inc.
  • Aurobindo Pharma, Ltd.
  • Vetter Pharma International GmbH
  • Thermo Fisher Scientific, Inc.
  • Catalent, Inc
  • Recipharm AB
  • Almac Group
  • Lonza Group Ltd.
  • Piramal Enterprises Limited
  • Fabbrica Italiana Sintetici S.p.A.
  • Fareva SA
  • C.H. Boehringer Sohn Ag & Co. KG.
  • Jubilant Pharmova Limited
  • Curia Global, Inc.

제10장 부록

KSM 22.06.21

List of Tables

  • Table 1 Global Pharmaceutical Contract Development and Manufacturing Market Drivers: Impact Analysis (2022-2029)
  • Table 2 Patent Expiration Of Top 15 Drugs
  • Table 3 Pharmaceutical R&D Spending by Top 10 Companies
  • Table 4 Expansions by CDMOs in HPAPI Development and Manufacturing (2020-2022)
  • Table 5 Consolidation in the Pharmaceutical Contract Development and Manufacturing Market
  • Table 6 Pharmaceutical Contract Development & Manufacturing: Expansions
  • Table 7 Global Pharmaceutical Contract Development and Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 8 Global Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 9 Pharmaceutical Contract Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 10 API Contract Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 11 Global FDF Contract Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 12 FDF Contract Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 13 Number Of Parenteral Drugs Approved in Relation To Total New Molecular Entity (NME) Approved (2015-2020)
  • Table 14 Parenteral/Injectable Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 15 Tablet Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 16 Capsule Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 17 Oral Liquid Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 18 Other Formulations Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 19 Contract Drug Development Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 20 Global Biologics Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 21 Biologics Contract Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 22 API Contract Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 23 FDF Contract Manufacturing Services Market Size, by Region/Country, 2020-2029 (USD Million)
  • Table 24 Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2020-2029 (USD Million)
  • Table 25 Pharmaceutical Contract Development and Manufacturing Market For Large Pharmaceutical Companies, by Country/Region, 2020-2029 (USD Million)
  • Table 26 Pharmaceutical Contract Development and Manufacturing Market For Small & Mid-Size Pharmaceutical Companies, by Country/Region, 2020-2029 (USD Million)
  • Table 27 Pharmaceutical Contract Development and Manufacturing Market For Generic Pharmaceutical Companies, by Country/Region, 2020-2029 (USD Million)
  • Table 28 Global Pharmaceutical Contract Development and Manufacturing Market Size, by Country/REGION, 2020-2029 (USD Million)
  • Table 29 North America: Pharmaceutical Contract Development and Manufacturing Market Size, by Country, 2020-2029 (USD Million)
  • Table 30 North America: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 31 North America: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 32 North America: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 33 North America: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 34 North America: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 35 Key Developments by Companies With Respect to COVID-19 Vaccine
  • Table 36 U.S.: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 37 U.S.: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 38 U.S.: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 39 U.S.: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 40 U.S.: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 41 Canada: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 42 Canada: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 43 Canada: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 44 Canada: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 45 Canada: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 46 Europe: Pharmaceutical Contract Development and Manufacturing Market Size, by Country/Region, 2020-2029 (USD Million)
  • Table 47 Europe: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 48 Europe: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)2
  • Table 49 Europe: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 50 Europe: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 51 Europe: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 52 Germany: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 53 Germany: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 54 Germany: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 55 Germany: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 56 Germany: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 57 Key Developments to Support Drug Development Services in the U.K.
  • Table 58 U.K.: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 59 U.K.: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 60 U.K.: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 61 U.K.: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 62 U.K.: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 63 France: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 64 France: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 65 France: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 66 France: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 67 France: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 68 Italy: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 69 Italy: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 70 Italy: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 71 Italy: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 72 Italy: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 73 Spain: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 74 Spain: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 75 Spain: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 76 Spain: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 99 Spain: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 100 Rest of Europe: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 101 Rest of Europe: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 102 Rest of Europe: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 104 Rest of Europe: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 105 Rest of Europe: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 106 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Size, by Country/Region, 2020-2029 (USD Million)
  • Table 107 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 108 Asia-Pacific: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 110 Asia-Pacific: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 112 Asia-Pacific: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 113 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 114 China: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 115 China: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 116 China: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 117 China: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 118 China: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 119 India: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 120 India: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 121 India: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 122 India: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 123 India: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 124 Japan: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 125 Japan: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 126 Japan: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 127 Japan: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 128 Japan: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 129 RoAPAC: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 130 RoAPAC: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 131 RoAPAC: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 132 RoAPAC: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 133 RoAPAC: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 134 Latin America: Pharmaceutical Contract Development and Manufacturing Market Size, by Country/Region, 2020-2029 (USD Million)
  • Table 135 Latin America: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 136 Latin America: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 137 Latin America: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 138 Latin America: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 139 Latin America: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 140 Brazil: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 141 Brazil: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 142 Brazil: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 143 Brazil: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 144 Brazil: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 145 Mexico: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 146 Mexico: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)6
  • Table 147 Mexico: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 148 Mexico: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 149 Mexico: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 150 RoLATAM: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 151 RoLATAM: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 152 RoLATAM: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 153 RoLATAM: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 154 RoLATAM: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 155 Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2020-2029 (USD Million)
  • Table 156 Middle East & Africa: Pharmaceutical Contract Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 157 Middle East & Africa: Pharmaceutical FDF Manufacturing Services Market Size, by Formulation, 2020-2029 (USD Million)
  • Table 158 Middle East & Africa: Biologics Manufacturing Services Market Size, by Type, 2020-2029 (USD Million)
  • Table 159 Middle East & Africa: Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2020-2029 (USD Million)
  • Table 160 Recent Developments, by Company, 2019-2022

List of Figures

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives interviewed
  • Figure 5 Breakdown Of Primary interviews (Supply-Side & Demand-Side)
  • Figure 6 Market Size Estimation
  • Figure 7 Global Pharmaceutical Contract Development and Manufacturing Market Size, by Service, 2022 VS. 2029 (USD Million)
  • Figure 8 Global Pharmaceutical Fdf Manufacturing Services Market Size, by Formulation, 2022 VS. 2029 (USD Million)
  • Figure 9 Global Pharmaceutical Contract Development and Manufacturing Market Size, by End User, 2022 VS. 2029 (USD Million)
  • Figure 10 Pharmaceutical Contract Development and Manufacturing Market Size, by Geography
  • Figure 11 Market Dynamics
  • Figure 12 Worldwide Sales for Generics (2018-2026)
  • Figure 13 Global Spending on Pharmaceutical Research and Development (USD Billion)
  • Figure 14 Global Pharmaceutical Contract Development and Manufacturing Services Market Size, by Type, 2022-2029 (USD Million)
  • Figure 15 Worldwide Generic Drug Sales (2018-2026)
  • Figure 16 Global Pharmaceutical Contract Development and Manufacturing Market, by End User, 2022-2029 (USD Million)
  • Figure 17 Global Pharmaceutical Contract Development and Manufacturing Market, by Region, 2022-2029 (USD Million)
  • Figure 18 North America: Pharmaceutical Contract Development and Manufacturing Market Snapshot
  • Figure 19 Europe: Pharmaceutical Contract Development and Manufacturing Market Snapshot
  • Figure 20 Biosimilar Consumption in Europe, 2018
  • Figure 21 Asia-Pacific: Pharmaceutical Contract Development and Manufacturing Market Snapshot
  • Figure 22 Latin America: Pharmaceutical Contract Development and Manufacturing Market Snapshot
  • Figure 23 Key Growth Strategies Adopted by Leading Players, 2019-2022
  • Figure 24 Pharmaceutical Contract Development and Manufacturing Market: Competitive Benchmarking, by Service
  • Figure 25 Market Share Analysis: Pharmaceutical Contract Development and Manufacturing Services Industry, 2021
  • Figure 26 Samsung Biologics Co., Ltd.: Financial Overview (2021)
  • Figure 27 Siegfried Holdings AG.: Financial Overview (2021)
  • Figure 28 FUJIFILM Holdings Corporation: Financial Overview (2020)
  • Figure 29 Aenova Group: Financial Overview (2020)
  • Figure 30 Wuxi Biologics Inc: Financial Overview (2021)
  • Figure 31 Aurobindo Pharma Ltd: Financial Overview (2020)
  • Figure 32 Thermo Fisher Scientific, Inc.: Financial Overview (2021)
  • Figure 33 Catalent, Inc: Financial Overview (2021)
  • Figure 34 Recipharm AB: Financial Overview (2020)
  • Figure 35 Lonza Group Ltd: Financial Overview (2021)
  • Figure 36 Piramal Enterprises Limited: Financial Overview (2020)
  • Figure 37 C.H. Boehringer Sohn Ag & Co. KG.: Financial Overview (2021)
  • Figure 38 Jubilant Pharmova Limited: Financial Overview (2020)

Pharmaceutical Contract Development & Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Global Forecast to 2029

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report presents key industry drivers, restraints, challenges, and opportunities. The growth of the pharmaceutical contract development and manufacturing market is mainly attributed to complex manufacturing requirements, patent expiration, increasing investments in pharmaceutical R&D, the pharmaceutical industry's inclination towards cutting-edge technologies, and the outbreak of the coronavirus pandemic. Moreover, the growing demand for cell and gene therapies and personalized medicines and the growth of the High-potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) markets offer significant opportunities for the players operating in the pharmaceutical contract development and manufacturing market.

Based on service, in 2022, the pharmaceutical manufacturing services segment is estimated to account for the largest share due to the growing need to reduce manufacturing costs, the use of advanced technologies and skills for manufacturing, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs. However, biologics manufacturing services is slated to be the fastest-growing segment during the analysis period due to the adoption of advanced technologies for biologics production, biopharma and pharma companies' inclination towards outsourcing their activities, increasing applications of monoclonal antibodies (mAbs), and the development of next-generation antibody therapies such as antibody-drug conjugates.

The API manufacturing services segment is expected to dominate the pharmaceutical contract manufacturing services market. The need to reduce the production cost of APIs, initiatives undertaken by pharmaceutical companies such as the development of new API manufacturing facilities, investments in API manufacturing services, agreements with other key players for expanding API manufacturing services, and the growing need to reduce the time required for drug development are expected to drive the growth of this segment.

Based on end user, the large pharmaceutical companies segment is estimated to command the largest share of the pharmaceutical contract development and manufacturing market in 2022. The rising incidence and prevalence of various diseases across the globe generating significant demand for effective medicines and breakthrough biopharmaceutical products and the growing need for state-of-the-art processes are the key factors driving the growth of the large pharmaceutical companies segment.

An in-depth analysis of the geographical scenario in the pharmaceutical contract development and manufacturing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is estimated to command the largest share of the pharmaceutical contract development and manufacturing market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG (Germany), Piramal Enterprises Limited (India), Almac Group (U.K.), Cambrex Corporation (U.S.), Samsung Biologics Co., Ltd (South Korea), Siegfried Holding AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), Aenova Group GmbH (Germany), WuXi Biologics (Cayman) Inc. (China), and Aurobindo Pharma Ltd. (India), among others.

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

  • Pharmaceutical Manufacturing Services
  • Pharmaceutical API Manufacturing Services
  • Pharmaceutical FDF Manufacturing Services
  • Parenteral/Injectable Manufacturing Services
  • Tablet Manufacturing Services
  • Capsule Manufacturing Services
  • Oral Liquid Manufacturing Services
  • Other Formulations Manufacturing Services
  • Drug Development Services
  • Biologics Manufacturing Services
  • Biologics API Manufacturing Services
  • Biologics FDF Manufacturing Services
  • Packaging Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

  • Large Pharmaceutical Companies
  • Small and Mid-size Pharmaceutical Companies
  • Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
      • 2.3.1.3. Growth Forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions For The Study
  • 2.5. Limitations For The Study

3. Executive Summary

4. Market insights

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Complex Manufacturing Requirements of the Pharmaceutical industry and Manufacturers' Growing inclination

Toward the Use of Cutting-Edge Technologies

    • 4.2.2. Rising Demand for Generic Medicines and Biologics
    • 4.2.3. Patent Expiration
    • 4.2.4. Increasing Investments in Pharmaceutical R&D
    • 4.2.5. Outbreak of the COVID-19 Pandemic
  • 4.3. Challenges
    • 4.3.1. Shortage of Skilled Professionals
    • 4.3.2. Introduction of Serialization
  • 4.4. Opportunities
    • 4.4.1. Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
    • 4.4.2. Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets
  • 4.5. Industry Trends
    • 4.5.1. Virtual Business Models
    • 4.5.2. Growing Consolidation Among CDMO Market Players

5. Pharmaceutical Contract Development and Manufacturing Services Market, by Type

  • 5.1. Introduction
  • 5.2. Pharmaceutical Manufacturing Services
    • 5.2.1. Active Pharmaceutical ingredient (API) Manufacturing Services
    • 5.2.2. Finished Dosage Forms (FDF) Manufacturing Services
      • 5.2.2.1. Parenteral/Injectable Manufacturing Services
      • 5.2.2.2. Tablet Manufacturing Services
      • 5.2.2.3. Capsule Manufacturing Services
      • 5.2.2.4. Oral Liquid Manufacturing Services
      • 5.2.2.5. Other Formulations
  • 5.3. Drug Development Services
  • 5.4. Biologics Manufacturing Services
    • 5.4.1. Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
    • 5.4.2. Finished Dosage Form Manufacturing (FDF) Services

6. Pharmaceutical Contract Development and Manufacturing Market, by End User

  • 6.1. Introduction
  • 6.2. Large Pharmaceutical Companies
  • 6.3. Small & Mid-Size Pharmaceutical Companies
  • 6.4. Generic Pharmaceutical Companies

7. Pharmaceutical Contract Development and Manufacturing Market, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe (RoE)
  • 7.4. Asia-Pacific
    • 7.4.1. China
    • 7.4.2. India
    • 7.4.3. Japan
    • 7.4.4. Rest of Asia-Pacific (ROAPAC)
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Rest of Latin America
  • 7.6. Middle East & Africa

8. Competitive Landscape

  • 8.1. Introduction
  • 8.2. Key Growth Strategies
  • 8.3. Competitive Benchmarking
  • 8.4. Market Share Analysis (2021) - TOP 19 Players
    • 8.4.1. Lonza Group Ltd. (Switzerland)
    • 8.4.2. Catalent INC. (U.S.)
    • 8.4.3. Thermo Fisher Scientific INC. (U.S.)
    • 8.4.4. Samsung Biologics Co., Ltd. (South Korea)
    • 8.4.5. Recipharm AB (Sweden)

9. Company Profiles (Business Overview, CDMO Facilities, Financial Overview, Service Portfolio, Strategic Developments)

  • 9.1. Cambrex Corporation
  • 9.2. Samsung Biologics Co., Ltd.
  • 9.3. Siegfried Holdings AG
  • 9.4. FUJIFILM Diosynth Biotechnologies
  • 9.5. Aenova Group
  • 9.6. Wuxi Biologics, Inc.
  • 9.7. Aurobindo Pharma, Ltd.
  • 9.8. Vetter Pharma international GmbH
  • 9.9. Thermo Fisher Scientific, Inc.
  • 9.10. Catalent, Inc
  • 9.11. Recipharm AB
  • 9.12. Almac Group
  • 9.13. Lonza Group Ltd.
  • 9.14. Piramal Enterprises Limited
  • 9.15. Fabbrica Italiana Sintetici S.p.A.
  • 9.16. Fareva SA
  • 9.17. C.H. Boehringer Sohn Ag & Co. KG.
  • 9.18. Jubilant Pharmova Limited
  • 9.19. Curia Global, Inc.

10. Appendix

  • 10.1. Questionnaire
  • 10.2. Available Customization
Back to Top
전화 문의
F A Q